United Kingdom

Avacta Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Avacta and LG Chem Life Sciences Expand Partnership

Lead Product(s): AVA6000

Therapeutic Area: Oncology Product Name: AVA6000

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: LG Chem

Deal Size: $453.5 million Upfront Cash: Undisclosed

Deal Type: Expanded Partnership August 18, 2020

Details:

Under the terms of the extended agreement, LG Chem has the exclusive rights to develop and commercialise, on a world-wide basis, Avacta’s Affimer PD-L1 inhibitor with Affimer XT serum half-life extension.

Oxford Biomedica

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generat...

Lead Product(s): Lentiviral vector

Therapeutic Area: Oncology Product Name: LentiVector

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Beam Therapeutics Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement August 03, 2020

Details:

The DMLA grants Beam a non-exclusive license to Oxford Biomedica’s LentiVector® platform for its application in next generation CAR-T programmes in oncology and puts in place a three year Clinical Supply Agreement.

Cancer Research

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Cancer Research UK, University of Southampton and Touchlight Genetics Partner to Develop Head and Neck Cancer Vaccine

Lead Product(s): TGL-100

Therapeutic Area: Oncology Product Name: TGL-100

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: University of Southampton

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 29, 2020

Details:

The new clinical development partnership aims at progressing a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).

F-star Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

F-star Therapeutics: Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration

Lead Product(s): Tetravalent bispecific antibodies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Merck Group

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 16, 2020

Details:

This is the second license option exercised by Merck KGaA, Darmstadt, Germany who, in May 2019, brought the first program from the collaboration into its pipeline.

F-star Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

F-star Therapeutics Presents Data on FS222 at 2020 AACR Annual Meeting

Lead Product(s): FS222

Therapeutic Area: Oncology Product Name: FS222

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

FS222 targets PD-L1 (programmed death-ligand 1), the immune checkpoint protein which regulates the balance of activated T cells in the immune system and CD137, a co-stimulatory molecule from the tumor necrosis factor receptor superfamily (TNFRSF).

Kymera Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor A...

Lead Product(s): KTX-201

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 11, 2020

Details:

The company will present preclinical data demonstrating that its STAT3 degraders downregulated immune checkpoint signals on tumor cells and positively modulated composition and activity of immune cells in the TME.

Almac Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Almac Discovery Enters Into Licensing Agreement for the Development & Commercialisation of ALM301

Lead Product(s): ALM301

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 14, 2020

Details:

The agreement aims at advancing the development and commercialisation of Almac's portfolio projects – ALM301. The molecule is currently in late-stage pre-clinical development, and the partner will complete this before progressing into the clinical development phase.

F-star Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

F-star Therapeutics Announces Positive Preclinical Antitumor Activity and Safety of FS222 Published in Clinical Cancer Research

Lead Product(s): FS222

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 28, 2020

Details:

Preclinical data show synergistic benefit of F-star’s tetravalent mAb² with evidence of robust CD4+ and CD8+ T cell activation which surpassed combinations of monoclonal antibodies in in-vitro assays.

Valo Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Valo Therapeutics Announces New Funding for Immuno-Oncology Trials

Lead Product(s): PeptiCRAd

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Finnish Funding Agency for Innovation

Deal Size: $10.9 million Upfront Cash: $1.2 million

Deal Type: Funding February 06, 2020

Details:

The funding will enable Valo Therapeutics to further validate their platform to develop antigen-coated oncolytic viruses as therapeutic vaccines.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Avacta Group

Avacta and LG Chem Life Sciences Expand Partnership

Oxford Biomedica

Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generat...

Cancer Research

Cancer Research UK, University of Southampton and Touchlight Genetics Partner to Develop Head and Neck Cancer Vaccine

F-star Therapeutics

F-star Therapeutics: Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration

F-star Therapeutics

F-star Therapeutics Presents Data on FS222 at 2020 AACR Annual Meeting

Kymera Therapeutics

Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor A...

Almac Group

Almac Discovery Enters Into Licensing Agreement for the Development & Commercialisation of ALM301

F-star Therapeutics

F-star Therapeutics Announces Positive Preclinical Antitumor Activity and Safety of FS222 Published in Clinical Cancer Research

Valo Therapeutics

Valo Therapeutics Announces New Funding for Immuno-Oncology Trials